Clinical trial · Interventional
Concurrent Xeloda and Radiotherapy for Bone Metastases
NCT00192777CI-TRIAL-00000909unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hypothesis: Radiosensitization using Xeloda should improve the rate of complete pain relief. Primary Objective: * To determine the frequency of pain relief for the proposed regimen. Secondary Objective(s): * To determine the duration of pain relief and narcotic relief for the proposed regimen. * To determine the frequency of narcotic relief for the proposed regimen. * To determine the toxicity of concurrent UFT and radiotherapy in patients with bone metastases.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Metastases | — | UNRESOLVED | — |
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| External Beam Radiotherapy | Procedure | — | UNRESOLVED |
| Xeloda | Drug | Capecitabine | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The frequency of pain relief for the proposed regimen, using a scale that takes into account the subjective feeling and the use of analgesics
- timeFrame
- after 3 months
Secondary outcomes (3)
- measure
- The duration of pain relief and narcotic relief for the proposed regimen after one year
- measure
- The frequency of narcotic relief for the proposed regimen after one year
- measure
- The toxicity of concurrent UFT and radiotherapy in patients with bone metastases after one year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. The patient must be 18 years of age or older. 2. The patient must have epithelial malignancy. 3. Radiographic evidence of bone metastasis is required. Acceptable studies include plain radiographs, radionuclide bone scans, computed tomography scans and magnetic resonance imaging. 4. The patient must have pain that appears to be related to the radiographically documented metastasis. 5. Patients must have an estimated life expectancy of 3 months or greater. 6. Signed study-specific informed consent. 7. Karnofsky performance status 40. 8. Calculated creatinine clearance \> 50 ml/min
References
Publications (0)
Data not yet available
No reference posted for this study.